144 related articles for article (PubMed ID: 27143896)
1. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis.
Fu J; Peng L; Li X
Neuropsychiatr Dis Treat; 2016; 12():951-9. PubMed ID: 27143896
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
Fu J; Chen Y
Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes.
Qin B; Huang G; Yang Q; Zhao M; Chen H; Gao W; Yang M
BMJ Open; 2019 Nov; 9(11):e033161. PubMed ID: 31784448
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.
Li G; Wang X; Ma D
Neuropsychiatr Dis Treat; 2016; 12():523-31. PubMed ID: 27013879
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study.
Yee A; Ng CG; Seng LH
Curr Drug Targets; 2018; 19(12):1412-1423. PubMed ID: 29149828
[TBL] [Abstract][Full Text] [Related]
9. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
12. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
15. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
Christensen MC; Loft H; Florea I; McIntyre RS
CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine for generalised anxiety disorder in adults.
Meza N; Leyton F
Medwave; 2021 Apr; 21(3):e8172. PubMed ID: 34038400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
